Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients

Movement Disorders

Volumn 19, Issue 2, 2004, Pages 192-196

  Stiasny Kolster, Karin ^a,c   Möller, J Carsten ^a   Zschocke, Johannes ^b   Bandmann, Oliver ^a   Cassel, Werner ^a   Oertel, Wolfgang H ^a   Hoffmann, Georg F ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Center of Nervous Diseases   (Germany)

Author keywords

Cerebrospinal fluid; Dopamine; Pathophysiology; Restless legs syndrome; Serotonin

Indexed keywords

3 O METHYLDOPA; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; 5 METHYLTETRAHYDROFOLIC ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOGENIC AMINE; DIHYDROBIOPTERIN; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; NEOPTERIN; SEROTONIN; TETRAHYDROBIOPTERIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE METABOLISM; DOPAMINE RELEASE; FEMALE; HUMAN; MALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SEROTONIN METABOLISM; SEROTONIN RELEASE; TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOGENIC AMINES; BRAIN; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RESTLESS LEGS SYNDROME; SEROTONIN;

EID: 1542300947     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10631     Document Type: Article

References (20)

1. Winkelmann J, Schadrack J, Wetter TC, Zieglgansberger W, Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. 2001;2:57-61.
2. Eisensehr I, Wetter TC, Linke R, Noachtar S, von Lindeiner H, Gildehaus FJ, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001;57:1307-1309.
3. Trenkwalder C, Walters AS, Hening WA, Chokroverty S, Antonini A, Dhawan V, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999;14:141-145.
4. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci 1996;142:151-152.
5. Hargrave R, Beckley DJ. Restless leg syndrome exacerbated by sertraline [letter]. Psychosomatics 1998;39:177-178.
6. Earley CJ, Hyland K, Allen RP. CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Mov Disord 2001;16:144-149.
7. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000;1: 11-19.
8. Allen R, Picchietti D, Hening W, Trenkwalder C, Walters AS, Montplaisir J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 2003;4:101-119.
9. Bräutigam C, Wevers RA, Jansen RJT, Smeitink JAM, Rijk-van Andel de JF, Gabreels FJM. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 1998;44:1897-1904.
10. LeWitt PA, Galloway MP. Neurochemical markers of Parkinson's disease. In: Koller WC, Paulson G, editors. Therapeutics in Parkinson's disease. New York: Marcel Dekker; 1990. p 63-93.
11. Espino A, Ambrosio S, Bartrons R, Bendahan G, Calopa M. Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. J Neural Transm 1994;7:167-176.
12. Gonzalez-Quevedo A, Garcia JC, Fernandez R, Fernandez Cartaya L. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system. Bol Estud Med Biol Mex 1993;41:13-19.
13. Tohgi H, Ueno M, Abe T, Takahashi S, Nozaki Y. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vaskular dementia of Binswanger. J Neural Transm Park Dis Dement Sect 1992;4:69-77.
14. Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of the Alzheimer type and vaskular. Influence of treatment with L-deprenyl. J Neural Transm Park Dis Dement Sect 1991;3:15-25.
15. Kaye JA, May C, Daly E, Atack JR, Sweeney DJ, Luxenberg JS, et al. Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features dementia. Neurology 1988;38:554-557.
16. Wallin A, Blennow K, Edman A, Mansson JE. Decreased lumbar cerebrospinal fluid levels of monoamine metabolites in vascular dementia. Int Psychogeriatr 1996;8:425-436.
17. Geracioti TDJ, Loosen PT, Ekhator NN, Schmidt D, Chambliss B, Baker DG, et al. Uncoupling of serotonergic and noradrenergic systems in depression: preliminary evidence from continuous cerebrospinal fluid sampling. Depress Anxiety 1997;6:89-94.
18. De Bellis MD, Geracioti TDJ, Altemus M, Kling MA. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry 1993;33:636-641.
19. Gjerris A, Sorensen AS, Rafaelsen OJ, Werdelin L, Alling C, Linnoila M. 5-HT and 5-HIAA in cerebrospinal fluid in depression. J Affect Disord 1987;12:13-22.
20. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-1579.